"Buchler, Tomas" . "I, N, V" . "RIV/00216224:14110/14:00078690!RIV15-MSM-14110___" . "GR - \u0158eck\u00E1 republika" . "Halamkova, Jana" . . . "2"^^ . "Anticancer Research" . "RIV/00216224:14110/14:00078690" . "0250-7005" . . "Kiss, Igor" . . "6"^^ . . "[A85279090B0F]" . . "Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma" . "000331497200056" . . "8"^^ . . "2" . . . . "Melichar, Bohuslav" . "14110" . "Poprach, Alexander" . . "Vyzula, Rostislav" . "The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively."@en . . "Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma"@en . "The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively." . "Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma" . . "Du\u0161ek, Ladislav" . . "Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma"@en . . . "Bortl\u00ED\u010Dek, Zbyn\u011Bk" . . "34" . "Colorectal cancer; metastasis; bevacizumab; chemotherapy; survival"@en . . "13813" .